|
[1]
|
Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer
Clinical Nuclear Medicine,
2021
DOI:10.1097/RLU.0000000000003505
|
|
|
|
|
[2]
|
Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer
Clinical Nuclear Medicine,
2021
DOI:10.1097/RLU.0000000000003505
|
|
|
|
|
[3]
|
124I Positron Emission Tomography/Computed Tomography Versus Conventional Radioiodine Imaging in Differentiated Thyroid Cancer: A Review
Thyroid,
2019
DOI:10.1089/thy.2018.0598
|
|
|
|
|
[4]
|
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer
The Quarterly Journal of Nuclear Medicine and Molecular Imaging,
2019
DOI:10.23736/S1824-4785.19.03201-1
|
|
|
|
|
[5]
|
Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in Triple-Negative Breast Cancer Patient
Cancer Biotherapy and Radiopharmaceuticals,
2018
DOI:10.1089/cbr.2018.2568
|
|
|
|
|
[6]
|
A phantom study: Should 124I‐mIBG PET/CT replace 123I‐mIBG SPECT/CT?
Medical Physics,
2017
DOI:10.1002/mp.12202
|
|
|
|
|
[7]
|
A phantom study: Should 124
I-mIBG PET/CT replace 123
I-mIBG SPECT/CT?
Medical Physics,
2017
DOI:10.1002/mp.12202
|
|
|
|
|
[8]
|
Lu-177 DOTATATE dosimetry for neuroendocrine tumor: single center experience
Journal of Physics: Conference Series,
2017
DOI:10.1088/1742-6596/851/1/012017
|
|
|
|
|
[9]
|
High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases
Journal of Nuclear Medicine,
2016
DOI:10.2967/jnumed.115.169649
|
|
|
|
|
[10]
|
Quantitative Comparison of 124I PET/CT and 131I SPECT/CT Detectability
Journal of Nuclear Medicine,
2016
DOI:10.2967/jnumed.115.162750
|
|
|
|
|
[11]
|
Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems
Annual Review of Biomedical Engineering,
2015
DOI:10.1146/annurev-bioeng-071114-040723
|
|
|
|